BPC-157: Proposed Mechanisms of Action
The signalling pathways most frequently proposed to explain BPC-157's reported effects, and what remains unresolved.
No dedicated receptor for BPC-157 has been characterised. The published mechanistic work instead describes modulation of several established systems.
VEGFR2 and angiogenesis
The most cited pathway involves activation of vascular endothelial growth factor receptor 2 in the absence of VEGF itself, followed by internalisation and downstream VEGFR2-Akt-eNOS signalling.
The nitric oxide system
Several studies describe counteraction of both NO-agonist and NO-antagonist effects, which the authors characterise as a homeostatic rather than directional influence.
Growth factor receptor expression
In tendon fibroblasts, increased growth hormone receptor expression is reported, offered as a link between the peptide and the tissue-level healing observations.
What is unresolved
Pharmacokinetics in humans, the fate of orally administered peptide, and whether the reported pathways are causal or downstream correlates all remain open questions.
Frequently asked questions
- What is the leading proposed mechanism?
- Activation and upregulation of VEGFR2, with downstream effects on angiogenesis, is the most frequently reported pathway in the literature.
- Does BPC-157 have a known receptor?
- No specific high-affinity receptor has been identified. Reported effects are attributed to modulation of existing signalling systems rather than a dedicated receptor.
Selected citations
- [01]
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Journal of Molecular Medicine, 2017
in vitroEndothelial cell culture with VEGFR2 knockdown controlsPMID 28110342 - [02]
Brain-gut axis and pentadecapeptide BPC 157
Current Neuropharmacology, 2016
animalNarrative review of rodent brain-gut axis experimentsPMID 26411462